
Doll D, Orlik A, Maier K, Kauf P, Schmid M, Diekmann M, Vogt AP, Stauffer VK, Luedi MM: Impact of geography and surgical approach on recurrence in global pilonidal sinus disease

Supplemental Figures and Tables


Australia/New Zealand



Supplemental Figure 1. Australia / New Zealand: Kaplan-Meier estimator depicting recurrence-free outcome of the study population as a function of follow-up time. The data used include all available studies from Italy. 95% confidence intervals are shown by shaded lines. Number of patients and CI 95% data included in the analysis are shown in Supplemental Table 1. Shaded lines indicate 95% confidence intervals

				-					d in Australia and New Zealand. Number of
patients included in the an	alysis and the acco	ording 959	<u>% CI are indicated</u>	at 0, 12,	24, 60, and 120 mc	onths. All	used citations fo	or the analysi	is are shown in the right column. I
Australia + New Zealand	12 months		24 months		60 months		120 months		Citations
Surgical method (total patients included)	RR in % (95% Cl)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	
Primary open (108)	0.9 (0.0-2.8)	108	1.1* (0.0-3.1)	106*	1.7* (0.0-4.2)	101*	NA	NA	114,624,625
Primary median closure (132)	17.4 (8.3-26.4)	77	21.2* (8.8-33.6)		32.6* (10.3-55.0)	42*	NA	NA	205,624,625
Primary asymmetric closure (104)	1.1* (0.1-2.0)	104*	2.1* (0.2-4.1)	104*	NA	NA	NA	NA	242
Karydiakis/Bascom (110)	0.7* (0.0-1.6)	110*	1.3* (0.0-3.3)	110*	NA	NA	NA	NA	270,626
Limberg/Dufourmentel (29)	0.0* (0.0-0.0)	29*	0.0* (0.0-0.0)	29*	NA	NA	NA	NA	627
Limited excision (137)	NA	NA	NA	NA	NA	NA	NA	NA	205
Flaps (57)	4.7* (1.1-8.2)	57*	9.4* (2.2-16.5)	57*	15.3* (3.6-27.1)	45*	NA	NA	460,628
Incision and drainage (22)	NA	NA	NA	NA	NA	NA	NA	NA	205
Phenol only (20)	0.0* (0.0-0.0)	20*	NA	NA	NA	NA	NA	NA	629
Others (27)	22.2 (1.6-42.8)	27	NA	NA	NA	NA	NA	NA	625


Asia



Supplemental Figure 2. Asia: Kaplan-Meier estimator depicting recurrence-free outcome of the study population as a function of follow-up time. The data used include all available studies from Italy. 95% confidence intervals are shown by shaded lines. Number of patients and CI 95% data included in the analysis are shown in Supplemental Table 2. Shaded lines indicate 95% confidence intervals

Supplemental Table 2: Recurrence rates in percent as a function of follow-up time of patients and all available surgical approaches applied in Asia. Number of patients included in the analysis and the according 95% CI are indicated at 0, 12, 24, 60, and 120 months. All used citations for the analysis are shown in the right column.									
Asia Surgical method (total patients included)	12 months		24 months		60 months		120 months		Citations
	RR in % (95% Cl)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	
Primary open (9)	0.0* (0.0-0.0)	9*	0.0* (0.0-0.0)	9*	NA	NA	NA	NA	106
Primary asymmetric closure (17)	0.0* (0.0-0.0)	17*	NA	NA	NA	NA	NA	NA	248
Flaps (7)	0.0* (0.0-0.0)	7*	0.0* (0.0-0.0)	7*	NA	NA	NA	NA	472
Phenol only (32)	0.0* (0.0-0.0)	32*	0.0* (0.0-0.0)	32*	NA	NA	NA	NA	630
Others (10)	NA	NA	NA	NA	NA	NA	NA	NA	512

Greece



Supplemental Figure 3. Greece: Kaplan-Meier estimator depicting recurrence-free outcome of the study population as a function of follow-up time. The data used include all available studies from Italy. 95% confidence intervals are shown by shaded lines. Number of patients and CI 95% data included in the analysis are shown in Supplemental Table 3.

Supplemental Table 3: Recur	rrence rates in perce	nt as a fun	ction of follow-up t	ime of pa	tients and all availab	le surgical	approaches applie	d in Greece. N	Number of patients included in the analysis and the
according 95% CI are indicate	ed at 0, 12, 24, 60, a	nd 120 mo	nths. All used citatio	ons for the	e analysis are shown	in the righ	t column		1
Greece	12 months		24 months		60 months		120 months		Citations
Surgical method (total patients included)	RR in % (95% CI)	Nr. at risk	RR in % (95% CI)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	RR in % (95% Cl)	Nr. at risk	
Primary open (52)	NA	NA	NA	NA	NA	NA	NA	NA	40
Primary median closure (43)	0.0* (0.0-0.0)	43*	NA	NA	NA	NA	NA	NA	631
Karydiakis/Bascom (7240)	0.0* (0.0-0.0)	7238*	0.1* (0.0-0.1)	7229*	0.3* (0.2-0.4)	7067*	0.9* (0.6-1.1)	NA	278,632,633
Limberg/Dufourmentel (142)	0.0* (0.0-0.0)	142*	0.0* (0.0-0.0)	137*	0.0* (0.0-0.0)	114*	NA	NA	364,634
									408,635
Marsupialisation (77)	0.0* (0.0-0.0)	77	0.0* (0.0-0.0)	55*	NA	NA	NA	NA	